**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 85027

**Manuscript Type:** CASE REPORT

**Primary ovarian angiosarcoma: Two case reports and review of literature**

Zhou Y *et al*. Primary oAS

Ying Zhou, Yi-Wen Sun, Xiao-Yang Liu, Dan-Hua Shen

**Ying Zhou, Yi-Wen Sun, Xiao-Yang Liu, Dan-Hua Shen,** Department of Pathology, Peking University People’s Hospital, Beijing 100044, China

**Author contributions:** Zhou Y and Sun YW designed the research study; Zhou Y, Sun YW and Liu XY performed the research; Zhou Y and Shen DH wrote the manuscript; and all authors have read and approve the final manuscript.

**Corresponding author: Dan-Hua Shen, Doctor, Chief Physician,** Department of Pathology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. shendanhua@pkuph.edu.cn

**Received:** April 8, 2023

**Revised:** June 5, 2023

**Accepted:** June 27, 2023

**Published online:**

**Abstract**

BACKGROUND

Angiosarcoma (AS) is a rare and highly aggressive soft tissue disease that most commonly arises in deep soft tissues. There are only a few reported cases of AS involving the ovary and even fewer reports of the underlying molecular abnormalities. Here, we briefly review two cases of primary ovarian AS (oAS) with specific molecular events and immune checkpoints. The clinical features and prognosis of the disease, diagnosis, differential diagnosis, and new treatment approaches are discussed based on a literature review.

CASE SUMMARY

Case 1: A 51-year-old female patient was admitted with right lower limb pain for 5 mo, and lower abdominal pain with hematuria for 1 mo. Partial removal of rectus abdominis muscle and fascia, partial hysterectomy, bilateral salpingo-oophorectomy, and inguinal and pelvic lymphadenectomy were performed. Pathology revealed primary oAS. Fluorescence *in situ* hybridization revealed *c-MYC* gene amplification. MESNA + ADM + IFO + DTIC (MAID) regimen was administered, but stable disease was achieved. The patient died 1 mo later. Case 2: A 41-year-old female patient presented with fatigue, nausea, decreased appetite, and diffuse abdominal pain. On physical examination, the abdomen was distended and a complex cystic mass was palpable in the right pelvic cavity. Pathology revealed primary oAS. MAID chemotherapy was administered and programmed death ligand 1 (PD-L1) staining was performed on the tumor samples. The patient benefited from anti-PD-1 immunotherapy and is alive without any evidence of disease 27 mo off therapy in follow-up.

CONCLUSION

Long-term survival benefit for primary oAS can be achieved by alternative therapeutic strategies using pathological indicators to inform treatment.

**Key Words:** Primary angiosarcoma; Ovarian; Therapy; Diagnosis; Prognosis; Case report

Zhou Y, Sun YW, Liu XY, Shen DH. Primary ovarian angiosarcoma: Two case reports and review of literature. *World J Clin Cases* 2023; In press

**Core Tip:** Angiosarcoma (AS) is a rare and highly aggressive type of soft tissue that most commonly arises in deep soft tissues. Alternative therapeutic strategies such as targeted therapies and anti-programmed cell death 1/programmed cell death ligand 1 therapy may be promising for primary ovarian AS.

**INTRODUCTION**

Angiosarcoma (AS) is a rare and highly aggressive soft tissue disease that most commonly arises in deep soft tissues[1], with only 1% of cases occurring in the ovarian system[2]. AS is generally associated with exposure to chemical substances, radiation, chronic lymphedema, and trauma.

Primary ovarian AS (oAS) is a highly aggressive neoplasm with rapid disease progression and poor prognosis[3]. Adjacent structures, including the small intestine, cecum, and uterus, are frequently involved. Metastases include those in the lungs, liver, lymph nodes, adrenal glands, bones, and brain[4]. Consequently, a better understanding of the oAS characteristics is urgently required.

Here, we present two cases of primary AS of the ovary: One with amplification of the c-MYC locus 8q21.24 and the other with positive programmed cell death protein 1 (PD-1, 22C3) immunohistochemical analysis. The clinical features, diagnosis, differential diagnosis, new treatment approaches, and prognosis of the disease are discussed based on a literature review.

**CASE PRESENTATION**

***Chief complaints***

**Case 1:** A 51-year-old female patient was admitted to our hospital on February 25, 2020, because of aggravated abdominal pain.

**Case 2:** A 41-year-old female patient presented with fatigue, nausea, decreased appetite, and diffuse abdominal pain.

***History of present illness***

**Case 1:** The patient had right lower limb pain for five months and lower abdominal pain with hematuria for one month.

**Case 2:** Since June 2018, the patient experienced intermittent lower abdominal distension and low back pain.

***History of past illness***

**Cases 1 and 2:** The patients had no history of illness. They had no medical or radiation history.

***Personal and family history***

**Cases 1 and 2:** The patient denied a family history of malignant tumors.

***Physical examination***

**Case 1:** Gynecological examination revealed an enlarged uterus and a hard, palpable mass in the right adnexal area.

**Case 2:** The abdomen was distended, and a complex cystic mass (major diameter: 10 cm) was palpable in the right pelvic cavity with poor mobility.

***Laboratory examinations***

**Cases 1 and 2:** Only serum carbohydrate antigen 125 (CA-125) tumor marker was elevated, 71.5 kU/L and 119.3 kU/L, respectively. Other markers were normal.

***Imaging examinations***

**Case 1:** A subsequent computed tomography scan of the abdomen and pelvis revealed a large solid mass (12.8 cm × 11.6 cm × 7.8 cm) in the right adnexal region, which invaded the right lower segment of the ureter, leading to obstruction and dilatation of the middle and upper segments of the ureter, and invaded the adjacent small intestine and cecum (Figure 1A).

**Case 2:** Magnetic resonance imaging documented a solid mass 10.3 cm × 9.2 cm in dimensions, uniform density, irregular margin, and unclear boundary in the right adnexal area. Malignant ovarian tumors were also considered. (Figure 2A).

***Further diagnostic work-up***

The postoperative pathological findings of the present two cases were as follows.

**Case 1:** On gross examination, the left ovary appeared unremarkable, and the right ovary was greatly enlarged and nodular, with cystic and solid, red-white cut surfaces. The small intestinal segment was densely adhered to the left colonic segment, with an intervening serosal mass. Multiple serosal deposits and lymph nodes were also isolated (Figure 1B). Upon microscopic examination, the tumor cells showed spindle-shaped, intercellular, slit-like structures, and neoplastic proliferation of atypical cells with enlarged pleomorphic nuclei and prominent [nucleoli](https://www.sciencedirect.com/topics/medicine-and-dentistry/nucleolus). Mitotic activity was high (12/10 high power fields). Extensive hemorrhage and necrosis were observed. The tumor cells showed positive immunohistochemical staining for caldesmon, CD31, and CD34. Approximately 50% of the cases were positive for cell proliferation-associated nuclear antigen (Ki-67) protein and negative for cytokeratin (CK), epithelial membrane antigen (EMA), CK5/6, desmin, CD10, p16, estrogen receptor alpha (ER), progesterone receptor (PR), programmed death ligand 1 (PD-L1), and placental prolactin protein. Due to the poor differentiation of the tumor cells and a Ki-67 high index, fluorescence *in situ* hybridization was performed, and c-MYC amplification was detected (Figures 3A-C).

**Case 2:** On gross examination, the right ovary was markedly swollen and completely displaced by a solid mass. The cut surface was red and the spongy areas occupied a substantial portion (Figure 2B). Microscopically, the tumor cells were composed of nail-like endothelial cells and a small number of scattered large cells arranged in a solid, fascicular, and tubular staggered arrangement. Vascular lacunae were formed in the area with an obvious lumen. Immunohistochemistry performed on a representative section showed strong and diffuse expression of vimentin, CD31, CD34, FLi-1, as well as a Ki-67 proliferative index that was focally increased up to 20%, while immunoreactions for calretinin, Pan cytokeratin monoclonal antibody, steroidogenic factor-1, EMA, PAX-8, WT-1, a-inhibin, ER, PR were all negative (Figures 4A-C).

**FINAL DIAGNOSIS**

**Case 1 and 2:** The final pathology returned as primary oAS.

**TREATMENT**

***Surgical procedure***

**Case 1:** Given the clinical presentation and significantly elevated serum CA-125 levels, an ovarian malignant tumor was suspected before surgery. The right ureter was wrapped by another mass measuring approximately 6 cm × 4 cm, and removal of the mass together with the involved ureter might cause a ureteral defect. Partial removal of the rectus abdominis muscle and fascia, partial hysterectomy, bilateral salpingo-oophorectomy, and inguinal and pelvic lymphadenectomy were performed first. The patient was administered neoadjuvant chemotherapy with six cycles of MESNA + ADM + IFO + DTIC (MAID) chemotherapy ([means](https://www.sciencedirect.com/topics/medicine-and-dentistry/coenzyme-m) 1500 mg/m2 on days 1-4, [doxorubicin](https://www.sciencedirect.com/topics/medicine-and-dentistry/doxorubicin) 20 mg/m2 on days 1-3, [ifosfamide](https://www.sciencedirect.com/topics/medicine-and-dentistry/ifosfamide) 2500 mg/m2 on days 1-3, and dacarbazine 300 mg/m2 on days 1-3). Responses were evaluated after two cycles of MAID; however, stable disease was achieved. The oncology department was consulted, and upon discussion of risks and benefits, the patient decided to participate in a clinical trial to take apatinib 500 mg orally once daily; however, she developed severe dermatitis and pleural effusion after undergoing a series of treatments. The dose was then halted. Her condition worsened clinically because of accumulation of ascitic fluid and shortness of breath. Palliative chemotherapy was administered as the disease was in its terminal stage.

**Case 2:** The patient underwent hysterectomy and bilateral salpingo-oophorectomy. Postoperatively, the patient received six cycles of MAID chemotherapy (mesna, adriamycin/doxorubicin, ifosfamide, and dacarbazine). Three months later, she experienced tumor recurrence with pelvic seeding; hence, she received a series of adjuvant chemotherapies again. In addition, PD-L1 (PD-L1 22C3 pharmDx antibody, Dako, Inc.) was performed on the tumor samples, which indicated PD-L1 focally up to 90% (Figure 2). As PD-1 checkpoint inhibition has seldom been investigated in AS, the oncology department was consulted upon discussion of treatment strategies for risks and benefits. The patient was treated with anti-PD-1 immunotherapy ([nivolumab](https://www.sciencedirect.com/topics/medicine-and-dentistry/nivolumab)).

**OUTCOME AND FOLLOW-UP**

**Case 1:** The death of the patient disease occurred 1 mo after treatment.

**Case 2:** The patient has survived without evidence of disease for 27 mo off therapy.

**DISCUSSION**

Primary oAS is very rare, with an incidence of one in one million malignant ovarian tumors. The clinical manifestations of primary oAS lack specificity, most of which are abdominal pain and masses, and some of which are long-term unexplained gastrointestinal or urinary symptoms. Among the tumor markers, serum CA-125 level is increased (49.2-189.1 kU/L), while the serum CA-199, α-fetoprotein, and carcinoembryonic antigen levels are mostly normal[5].

The differential diagnosis of oAS mainly focuses on pathological diagnosis. Primary oAS has complex and diverse histomorphology, consisting of endothelial cells with varying degrees of atypia. When well-differentiated, they form lumps, and when poorly-differentiated, only single-cell lacunae can be observed. The diagnosis of primary oAS should be combined with the results of routine pathological examinations and immunohistochemistry panels, especially positive endothelial cell markers (mainly CD31, CD34, FV, and vimentin)[6]. Therefore, oAS may present a challenge for intraoperative frozen section diagnosis of an ovarian mass[7].

Primary oAS should be differentiated from benign vascular hyperplasia, ovarian hemangiomas, juvenile hemangioendotheliomas, and other benign lesions. Immunohistochemical detection of vascular endothelial cell markers in these lesions was positive; however, the tumor cells lacked atypia. Primary oAS should be differentiated from malignant melanoma, leiomyosarcoma, and other malignant tumors. Malignant melanoma is positive for the S100 protein, anti-melanoma-specific antibody, and melanoma differentiation antigen. Leiomyosarcoma is positive for myogenic markers, such as desmin, smooth muscle actin, and caldesmon[8]. Tumor size at the time of diagnosis and the presence or absence of metastases are the most important prognostic factors for primary oAS. The prognosis of tumors < 5 cm in diameter is significantly better than that of tumors > 5 cm[9].

Presently, treatment strategies vary, but none have produced substantial long-term success[10]. The commonly used chemotherapy regimens for primary oAS include MAID[11], ifosfamide + doxorubicin, and gemcitabine + cisplatin[12]. Primary oAS with c-MYC amplification or high PD-L1 expression is rare. Understanding the progress in molecular pathological research on AS and searching for possible effective targets for targeted therapy is the hope of prolonging the survival of patients[13-17].

In many cases, c-MYC amplification is associated with prognosis by mediating acquired resistance to anticancer therapies. Although c-MYC has been extensively investigated as a therapeutic target for various cancers, including radiation-induced and secondary AS[18], there are few studies have examined the clinical significance of c-MYC [gene amplification](https://www.sciencedirect.com/topics/medicine-and-dentistry/gene-amplification) in primary oAS[19].

The treatment of AS with c-MYC [gene amplification](https://www.sciencedirect.com/topics/medicine-and-dentistry/gene-amplification) has been discussed in a few case reports[20-22]. In a previous study, patients with radiation-induced abdominal AS exhibited a dramatic response to apatinib[23]. Due to the rarity of incidents and lack of clinical treatment experience, we referred to suggestions for experimental drug use, but our patient showed apatinib resistance and little effect was achieved. It remains unclear whether apatinib resistance is related to radiation-induced genesis, location of the primary tumor, or potential molecular factors. Further clinical studies are warranted to corroborate these findings, and treatment with c-MYC inhibitors may be suggested as an alternative therapeutic strategy for this subset of patients.

Recently, several [monoclonal antibodies](https://www.sciencedirect.com/topics/medicine-and-dentistry/monoclonal-antibody) targeting PD-1 or its ligand PD-L1 have been associated with favorable outcomes in some solid tumors in large clinical trials[24-26]. A strong predictive association has been validated between PD-L1 expression and clinical outcomes for PD-1/PD-L1 inhibitors, and PD-1 and PD-L1 were evaluated in certain tumor specimens using specialized immunohistochemical techniques to determine PD-L1 immunoreactivity in tumor cells[27]. PD-1 checkpoint inhibition has seldom been investigated in AS and may have therapeutic utility[28,29]. In our second case, because of metastasis and it was unclear what additional treatment was performed at that time, patients’ tumors were evaluated for PD-L1 expression with PD-L1 22C3 pharmDx antibody (Dako, Inc.) and showed strong PD-L1 expression (average of 50%, hotpot with 99%). The patient benefited from anti-PD1/PD-L1 therapy treated with [nivolumab](https://www.sciencedirect.com/topics/medicine-and-dentistry/nivolumab). Although it is not possible to draw conclusions about the prognosis or potential therapies in this case, an evaluation of the effectiveness of [immune checkpoint inhibitors](https://www.sciencedirect.com/topics/medicine-and-dentistry/immune-checkpoint-inhibitor) for oAS is awaited[30].

**CONCLUSION**

Primary oAS is very rare;surgical resection combined with postoperative adjuvant chemotherapy is the first-line treatment but has not shown long-term survival benefits. The diagnosis of this disease depends on the pathological diagnosis, and the detection of certain pathological indicators also provides more evidence for clinical treatment. Alternative therapeutic strategies, such as targeted therapies and anti-PD1/PD-L1 therapy treatment be promising for primary oAS.

**REFERENCES**

1 **Deb PQ**, Weiss RE, Heller DS. Angiosarcoma of the Uterus: A Systematic Review. *Int J Gynecol Pathol* 2022; **41**: 496-502 [PMID: 34723849 DOI: 10.1097/PGP.0000000000000833]

2 **Bradford L**, Swartz K, Rose S. Primary angiosarcoma of the ovary complicated by hemoperitoneum: a case report and review of the literature. *Arch Gynecol Obstet* 2010; **281**: 145-150 [PMID: 19396453 DOI: 10.1007/s00404-009-1092-2]

3 **Furihata M**, Takeuchi T, Iwata J, Sonobe H, Ohtsuki Y, Wakatsuki A, Morioka N, Sagara Y. Primary ovarian angiosarcoma: a case report and literature review. *Pathol Int* 1998; **48**: 967-973 [PMID: 9952341 DOI: 10.1111/j.1440-1827.1998.tb03868.x]

4 **Vavilis D**, Papadopoulos N, Agorastos T, Efstratiou I, Kommoss F, Bontis IN. Primary ovarian angiosarcoma--review of the literature and report of a case with coexisting chylothorax. *Eur J Gynaecol Oncol* 2007; **28**: 287-289 [PMID: 17713094]

5 **Young RJ**, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. *Lancet Oncol* 2010; **11**: 983-991 [PMID: 20537949 DOI: 10.1016/S1470-2045(10)70023-1]

6 **May Lee M**, Pierobon E, Riva G, Germi L, Feliciani C, Naldi L. Angiosarcoma and Vascular Surgery: A Case Report and Review of Literature. *Vasc Endovascular Surg* 2022; **56**: 762-766 [PMID: 35694959 DOI: 10.1177/15385744221108248]

7 **Khunamornpong S**, Settakorn J, Sukpan K, Pongsuvareeyakul T, Siriaunkgul S. Angiosarcoma Arising in Ovarian Mucinous Tumor: A Challenge in Intraoperative Frozen Section Diagnosis. *Case Rep Pathol* 2016; **2016**: 8508624 [PMID: 27872782 DOI: 10.1155/2016/8508624]

8 **Glazebrook KN**, Magut MJ, Reynolds C. Angiosarcoma of the breast. *AJR Am J Roentgenol* 2008; **190**: 533-538 [PMID: 18212243 DOI: 10.2214/AJR.07.2909]

9 **Quesenberry CD**, Li C, Chen AH, Zweizig SL, Ball HG 3rd. Primary angiosarcoma of the ovary: a case report of Stage I disease. *Gynecol Oncol* 2005; **99**: 218-221 [PMID: 16081151 DOI: 10.1016/j.ygyno.2005.05.044]

10 **Messiou C**, Moskovic E, Vanel D, Morosi C, Benchimol R, Strauss D, Miah A, Douis H, van Houdt W, Bonvalot S. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. *Eur J Surg Oncol* 2017; **43**: 1191-1198 [PMID: 28057392 DOI: 10.1016/j.ejso.2016.10.032]

11 **Li EX**, Zhang YT, Shang JT, Xu Z, Geng Y, Li SM, Shi F, Wu YY. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma]. *Ai Zheng* 2006; **25**: 1048-1051 [PMID: 16965692]

12 **Liu R**, Chen D, Dong F, Zheng MH. [Advances in molecular pathology of primary cardiac angiosarcoma]. *Zhonghua Bing Li Xue Za Zhi* 2023; **52**: 87-90 [PMID: 36617920 DOI: 10.3760/cma.j.cn112151-20220531-00477]

13 **Yang L**, Liu L, Han B, Han W, Zhao M. Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report. *BMC Cancer* 2018; **18**: 618 [PMID: 29855279 DOI: 10.1186/s12885-018-4523-2]

14 **Jones RL**, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. *JAMA Oncol* 2022; **8**: 740-747 [PMID: 35357396 DOI: 10.1001/jamaoncol.2021.3547]

15 **Panda SP**, Panigrahy UP, Prasanth D, Gorla US, Guntupalli C, Panda DP, Jena BR. A trimethoxy flavonoid isolated from stem extract of Tabebuia chrysantha suppresses angiogenesis in angiosarcoma. *J Pharm Pharmacol* 2020; **72**: 990-999 [PMID: 32311118 DOI: 10.1111/jphp.13272]

16 **Pink D**, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, Richter S, Lindner LH, Szkandera J, Grünwald V, Kebenko M, Kirchner M, Hohenberger P. Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06). *Cancers (Basel)* 2021; **13** [PMID: 33799576 DOI: 10.3390/cancers13061223]

17 **Wagner MJ**, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, Ravi V, Holland EC, Sood AK. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. *Sci Rep* 2021; **11**: 9362 [PMID: 33931674 DOI: 10.1038/s41598-021-88703-9]

18 **Yan M**, Gilmore H, Bomeisl P, Harbhajanka A. Clinicopathologic and immunohistochemical study of breast angiosarcoma. *Ann Diagn Pathol* 2021; **54**: 151795 [PMID: 34392127 DOI: 10.1016/j.anndiagpath.2021.151795]

19 **Abada E**, Jang H, Kim S, Ali-Fehmi R, Bandyopadhyay S. A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma. *J Pathol Transl Med* 2022; **56**: 342-353 [PMID: 36288741 DOI: 10.4132/jptm.2022.08.31]

20 **Webb C**, Partain N, Koduru P, Hwang H, Sarode VR. Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature. *Int J Surg Pathol* 2021; **29**: 205-210 [PMID: 32552130 DOI: 10.1177/1066896920930100]

21 **Fraga-Guedes C**, André S, Mastropasqua MG, Botteri E, Toesca A, Rocha RM, Peradze N, Rotmensz N, Viale G, Veronesi P, Gobbi H. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression. *Breast Cancer Res Treat* 2015; **151**: 131-140 [PMID: 25893585 DOI: 10.1007/s10549-015-3379-2]

22 **Yonezawa I**, Waki M, Tamura Y, Onoda R, Narushima M, Ishizuka T, Tajima S. Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification. *Curr Oncol* 2014; **21**: e782-e789 [PMID: 25489268 DOI: 10.3747/co.21.2144]

23 **Guan J**, Luo Z, Xiao Z, Xie Y, Lin L. Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report. *BMC Cancer* 2019; **19**: 1188 [PMID: 31805975 DOI: 10.1186/s12885-019-6351-4]

24 **Reck M**, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2016; **375**: 1823-1833 [PMID: 27718847 DOI: 10.1056/NEJMoa1606774]

25 **Horn L**, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *J Clin Oncol* 2017; **35**: 3924-3933 [PMID: 29023213 DOI: 10.1200/JCO.2017.74.3062]

26 **Rittmeyer A**, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017; **389**: 255-265 [PMID: 27979383 DOI: 10.1016/S0140-6736(16)32517-X]

27 **Filiukova OB**, Snastina TI, Belotskiĭ SM, Marchuk AI, Timin EN. [Stimulation of the respiratory burst of the neutrophils from healthy subjects by different Staphylococcus aureus concentrations]. *Zh Mikrobiol Epidemiol Immunobiol* 1987: 58-60 [PMID: 3591126 DOI: 10.7759/cureus.26323]

28 **Sindhu S**, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. *J Immunother Cancer* 2017; **5**: 58 [PMID: 28716069 DOI: 10.1186/s40425-017-0263-0]

29 **Boichard A**, Wagner MJ, Kurzrock R. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. *Genome Med* 2020; **12**: 61 [PMID: 32646514 DOI: 10.1186/s13073-020-00753-2]

30 **Ye H**, Lin M, Li R, Qin S, Hou G, Chen H, Li X. Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor. *J Ovarian Res* 2021; **14**: 21 [PMID: 33509230 DOI: 10.1186/s13048-021-00771-7]

**Footnotes**

**Informed consent statement:** Written informed consent has been obtained from the patient for publication of this case report.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 8, 2023

**First decision:** May 31, 2023

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Bredt LC, Brazil; Ghazy A, Egypt **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ


**Figure Legends**




**Figure 1 Computed tomography findings and macroscopic observation for case 1.** A: Computed tomography scan revealed a large solid mass in the right adnexal region, with a size of 12.8 cm × 11.6 cm × 7.8 cm (yellow arrow) leading to obstruction and dilatation of the middle and upper segment of the ureter, and invading the adjacent area; B: Right ovary was greatly enlarged and nodular with cystic and solid, reddish-white cut surface ureter (red arrow), and invaded the right lower segment of the ureter (yellow arrow).



**Figure 2 Magnetic resonance imaging findings and macroscopic observation for case 2.** A: Magnetic resonance imaging documented a solid mass 10.3 cm × 9.2 cm in dimensions, uniform density, regular margin, and unclear boundary in the right adnexal area ureter; B: The right ovary was markedly swollen, and it was totally displaced by a solid mass. The cut surface was red; spongy areas occupied a substantial portion.



**Figure 3 Pathological findings of case 1.** A: Tumor cells showed spindle-shaped, intercellular slit-like structures, neoplastic proliferation of atypical cells, with enlarged pleomorphic nuclei and prominent nucleoli (hematoxylin and eosin, × 4); B: Expression of cell Ki-67 protein was positive in 30% (× 10); C: Fluorescence in situ hybridization detected c-MYC amplification.



**Figure 4 Pathological findings of case 2.** A: Tumor cells showed positive immunohistochemical reaction for CD31 (× 10); B: Residual leucosome ovarian tissue can be seen around the tumor tissue (hematoxylin and eosin, × 10); C: Immunohistochemical staining showed tumor cells strongly expressed programmed death ligand 1 (average with 50%, hotpot with 99%) (× 10).